Get access

Increased high-sensitivity C-reactive protein levels in Taiwanese schizophrenic patients

Authors

  • Chin-Chuen Lin MD,

    1. Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
    Search for more papers by this author
  • Chia-Ming Chang MD,

    1. Department of Psychiatry, Chang Gung Memorial Hospital, Linkou, and Chang Gung University College of Medicine, Taoyuan, Taiwan
    Search for more papers by this author
  • Chia-Yih Liu,

    1. Department of Psychiatry, Chang Gung Memorial Hospital, Linkou, and Chang Gung University College of Medicine, Taoyuan, Taiwan
    Search for more papers by this author
  • Tiao-Lai Huang MD

    Corresponding author
    • Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
    Search for more papers by this author

  • Funding sources: No financial assistance was obtained from any pharmaceutical company.
  • Author contribution: Huang TL, Chang CM, and Liu CY conceptualized and designed the immunological aspects of the study and formulated the hypotheses and analytical strategies. Lin CC wrote the manuscript.

Correspondence

Tiao-Lai Huang MD, Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niao-Sung District, Kaohsiung 833, Taiwan.

Tel: +886 7731 7123 ext. 8753

Fax: +886 7732 6817

Email: a540520@adm.cgmh.org.tw

Abstract

Introduction

Schizophrenia is associated with the activation of the immune/inflammatory system. C-reactive protein (CRP), a positive acute phase protein, may be associated with schizophrenia and antipsychotic treatment.

Methods

The serum high-sensitivity CRP (hsCRP) levels of 36 schizophrenic patients undergoing clozapine, olanzapine or risperidone treatment and 36 sex-matched healthy subjects were collected. The difference in hsCRP levels between the schizophrenic and the control groups was estimated using ancova. anova was performed to examine the differences in the hsCRP levels between three antipsychotic groups (clozapine, olanzapine and risperidone).

Results

ancova adjusted for age and body mass index (BMI) revealed a significant increase in the hsCRP levels in the schizophrenic group (1.4 mg/L, SD =1.5 mg/L) in comparison with the control group (0.9 mg/L, SD = 1.4 mg/L) (P = 0.013). anova revealed no statistical difference of age, BMI and hsCRP in three antipsychotic groups (P = 0.83, 0.90 and 0.71, respectively).

Discussion

The elevation of CRP level is seen in chronic schizophrenia under antipsychotic treatment; however, studies with a larger sample size are required to confirm these results.

Get access to the full text of this article

Ancillary